News | Clinical Trials | November 15, 2019

The prospective open-label study met its primary and secondary endpoints

 Prostate cancer MRI

November 15, 2019 — Theragnostics, which is developing innovative radiopharmaceuticals to improve cancer diagnosis and treatment, announced the successful completion of a phase two clinical study of novel prostate cancer diagnostic imaging Gallium-68 (68Ga) THP-PSMA PET/CT.

The PRONOUNCED trial is a prospective open-label study of 50 patients to evaluate the safety and clinical impact of 68Ga THP-PSMA PET/CT imaging (THP-PSMA) on patient management and treatment decisions in men who are newly diagnosed or have biochemically recurrent prostate cancer after initial treatment.

The study met its primary and secondary endpoints. Data demonstrates that post THP-PSMA scan, one third of newly diagnosed prostate cancer patients, and over 50 percent of patients with biochemically recurrent disease including 75 percent in a post-radical radiotherapy setting, saw their treatment plan altered to be more appropriate as a result of re-staging their prostate cancer. The safety data showed that THP-PSMA was well tolerated with no serious adverse events reported and was therefore considered safe.

"The PRONOUNCED study was completed with a substantial number of changes to the treatment regime made following the THP-PSMA scan and shows how this exciting technology can influence the management of prostate cancer patients," said Professor Jamshed Bomanji, co-investigator and head of department at the Institute of Nuclear Medicine, UCLH. "The new THP-PSMA PET/CT imaging allows for prospective analysis of the clinical disease status rather than retrospective, allowing for better informed decision making."

Greg Mullen, PhD., CEO of Theragnostics added, "We are very pleased that the PRONOUNCED trial has completed with such a positive result, this combined with a positive meeting with the FDA earlier this year on our route to NDA submission are key milestones in bringing THP-PSMA to patients. We are convinced that a THP-PSMA scan will benefit the treatment of prostate cancer patients by better informed and faster decision making. We look forward to sharing these data with the medical community at upcoming scientific congresses and in peer-reviewed publications."

The trial is jointly funded by Innovate UK and Theragnostics and conducted at University College London Hospitals NHS Foundation Trust (UCLH) with multiple referral sites in the UK including Guys and St. Thomas' NHS Foundation Trust (GSTT), Barts Health NHS Trust, Royal Free London NHS Foundation Trust. The study was led by Dr. Asim Afaq, UCLH Consultant Radiologist at the Institute of Nuclear Medicine, together with UCLH uro-oncology colleagues including Professor Heather Payne, Dr Reena Davda, Mr John Hines and Prof Gary Cook, Professor of Clinical PET imaging at King's College London and GSTT.

The study was completed with support from the National Institute for Health Research University College London Hospitals Biomedical Research Centre and the Cancer Research UK University College London Experimental Cancer Medicine Centre.

For more information: www.theragnostics.com

 


Related Content

News | Breast Imaging

January 24, 2023 — For patients with cancer, lengthy delays in treatment can decrease their chances of survival. In an ...

Time January 24, 2023
arrow
News | Lung Imaging

January 23, 2023 — A study published in the January issue of The Journal of Nuclear Medicine reports that approximately ...

Time January 23, 2023
arrow
News | Digital Pathology

January 19, 2023 — In an effort to speed up the research study process, Deciphex has announced the rollout of its ...

Time January 19, 2023
arrow
News | Cardiac Imaging

January 13, 2023 — Nuclear stress testing performed with single-photon emission computed tomography (SPECT) is the most ...

Time January 13, 2023
arrow
News | Radiopharmaceuticals and Tracers

January 11, 2023 — NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and ...

Time January 11, 2023
arrow
News | Molecular Imaging

January 5, 2023 — A new study has determined that approximately three percent of all bone scan patients have markers of ...

Time January 04, 2023
arrow
News | Nuclear Imaging

January 2, 2023 — The federal agency that oversees the administration of nuclear medicine has announced that it will ...

Time January 02, 2023
arrow
News | Proton Therapy

January 2, 2023 — IBA, a world leader in particle accelerator technology, today confirms that it has signed a contract ...

Time January 02, 2023
arrow
News | Breast Imaging

December 29, 2022 — Anthracyclines are a class of chemotherapies effective in treating many forms of cancer, including ...

Time December 29, 2022
arrow
News | Lung Imaging

December 26, 2022 — Artificial intelligence (AI) could help identify the risk of cancer returning in non-small cell lung ...

Time December 26, 2022
arrow
Subscribe Now